Akut Miyeloid Lösemi AML

Öz

Akut miyeloid lösemi AML çocuklarda ikinci en sık lösemi türüdür. AML tanısı için kemik iliğinde % 30’un üstünde blast varlığı gereklidir. Destekleyici bakımdaki iyileşmeler- le birlikte yoğunlaştırılmış konvansiyonel kemoterapi çocukluk çağı AML prognozunu iyileştirmiştir. AML olan çocukların tedavisinde gelişmeler, lökomogenezin ve ilaç direncinin altında yatan genetik anormallikler dikkate alı- narak hastalığın biyolojisinin daha iyi anlaşılmasını gerek- tirir. Bu yazımızda AML genetik ve biyolojisine yeni bir bakış açısı sağlayan son çalışmaları, hastalık için risk sınıflaması ve tedavi tartışmalarını ve halen araştırılmakta olan terapötik ajanları özetledik

Anahtar Kelimeler

• Akut miyeloid lösemi,AML,çocukluk çağı lösemisi

Acute Myelogenous Leukemia AML

Öz

Acute myelogenous leukemia AML is the second most com- mon leukemia in children. The diagnosis of AML requires the presence of blasts >30% in the bone marrow in most cases. The intensification of conventional chemotherapy along with improvements in supportive care has improved the prognosis in childhood AML. Instead, advances in the treatment of child- ren with AML will require a greater understanding of the biology of the disease, with particular attention to the genetic abnormalities underlying leukemogenesis and drug resistan- ce. In this review, we summarize recent studies that provide new insight into the genetics and biology of AML, discuss risk stratification and therapy for this disease, and profile some of the therapeutic agents currently under investigation

Anahtar Kelimeler

• Acute myeloid leukaemia,AML,childhood leukaemia

Kaynakça

1. Weinblatt ME, Arceci RJ, et al. Pediatric acute myelocytic leukemia. Emedicine, Medscape Reference, Updated: Sep 12, S, Aydoğan G, Çetin M et al (eds). Pediatrik Hematoloji. İstanbul Tıp Kitabevi, 1. Baskı, İstanbul, 2011;623-40.
2. Tubergen DG, Bleyer A. The Leukemias. Kliegman RM, Behrman RE, Jenson HB, Stanton BF (eds). In Nelson Textbook of Pediatrics, 18th ed. Philadelphia, Saunders, Elsevier Inc., 2007. Chapter 495: 2116-22.
3. Pediatric Hematology and Oncology, 4th ed. Burlington, San Diego London, Elsevier Academic Press, 2005;14:415-51.
4. Kean LS, Arceci RJ, Woods WG. Acute Myeloid Leukemia. Arceci RJ, Hann IM, Smith OP (eds). In Pediatric Hematology. rd ed. Oxford, Blackwell Publishing, 2006. Section 4, Chapter 16:360-383. PMid:20113895
5. Hematol Oncol Clin North Am 2010;24:35-63. http://dx.doi.org/10.1016/j.hoc.2009.11.008 PMid:20113895 tive features of patients with acute myeloid leukemia. Neoplasma 2006;53(2):155-60. PMid:16575472 towards high-quality cure of all patients. Haematologica ;92:1519-32. http://dx.doi.org/10.3324/haematol.11203 PMid:18024401
6. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an internati- onal expert panel. Blood 2012;120:3187-205. http://dx.doi.org/10.1182/blood-2012-03-362608 PMid:22879540
7. Rubnitz JE, Hiroto Inaba. Childhood acute myeloid leukae- mia. British Journal of Haematology 2012;159:259-87. http://dx.doi.org/10.1111/bjh.12040 PMid:22966788
8. Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®), National Cancer Institute, ;1-14. review on allogeneic stem cell transplantation for newly diag- nosed pediatric acute myeloid leukemia. Prepublished online June 10, 2010. http://dx.doi.org/10.1182/blood-2010-01-261800